Efficacy and Safety of Altibrain(®) as an Adjunctive Therapy for Autism Spectrum Disorder: An Open Label Trial Targeting Core Symptoms.

Mehan S, Kumar A, Utage PR, Hegde A, Naik N, Kondekar S, Yardi N, Desai N, Panigrahi D, Chattopadhyay A, Agarwal SD, Gupta VB, Tiwari A, Reddy SC, Saraf S, Das D, Detroja M, Paliwal C

Open source

DOI: 10.2174/0113816128335544241210144541
Published: 2025
Container: Current pharmaceutical design
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2174/0113816128335544241210144541,
  title = {Efficacy and Safety of Altibrain(®) as an Adjunctive Therapy for Autism Spectrum Disorder: An Open Label Trial Targeting Core Symptoms.},
  author = {Mehan S and Kumar A and Utage PR and Hegde A and Naik N and Kondekar S and Yardi N and Desai N and Panigrahi D and Chattopadhyay A and Agarwal SD and Gupta VB and Tiwari A and Reddy SC and Saraf S and Das D and Detroja M and Paliwal C},
  year = {2025},
  journal = {Current pharmaceutical design},
  doi = {10.2174/0113816128335544241210144541},
  url = {https://doi.org/10.2174/0113816128335544241210144541}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Altibrain(®) as an Adjunctive Therapy for Autism Spectrum Disorder: An Open Label Trial Targeting Core Symptoms.
AU  - Mehan S
AU  - Kumar A
AU  - Utage PR
AU  - Hegde A
AU  - Naik N
AU  - Kondekar S
AU  - Yardi N
AU  - Desai N
AU  - Panigrahi D
AU  - Chattopadhyay A
AU  - Agarwal SD
AU  - Gupta VB
AU  - Tiwari A
AU  - Reddy SC
AU  - Saraf S
AU  - Das D
AU  - Detroja M
AU  - Paliwal C
PY  - 2025
JO  - Current pharmaceutical design
DO  - 10.2174/0113816128335544241210144541
UR  - https://doi.org/10.2174/0113816128335544241210144541
ER  -

APA

S, M., A, K., PR, U., A, H., N, N., S, K., N, Y., N, D., D, P., A, C., SD, A., VB, G., A, T., SC, R., S, S., D, D., M, D., & C, P. (2025). Efficacy and Safety of Altibrain(®) as an Adjunctive Therapy for Autism Spectrum Disorder: An Open Label Trial Targeting Core Symptoms.. Current pharmaceutical design. https://doi.org/10.2174/0113816128335544241210144541

Source records

pubmed · retrieved 2026-09-26T07:23:36.994Z